Esophageal cancer: Clinical Practice Guidelines in oncology™

Jaffer Ajani, Tanios Bekaii-Saab, Thomas A. D'Amico, Charles Fuchs, Michael K. Gibson, Melvyn Goldberg, James A. Hayman, David H. Ilson, Milind Javle, Scott Kelley, Robert C. Kurtz, Gershon Yehuda Locker, Neal J. Meropol, Bruce D. Minsky, Mark B. Orringer, Raymond U. Osarogiagbon, James A. Posey, Jack Roth, Aaron R. Sasson, Stephen G. SwisherDouglas E. Wood, Yun Yen

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Esophageal cancer is a major health hazard in many parts of the world. The incidence of adenocarcinoma is increasing in white men, particularly in the nonendemic areas such as North America and many Western European countries. Barrett's metaplasia, gastroesophageal reflux, hiatal hernia, and obesity are believed to be contributing factors. In addition, the most common location of esophageal carcinoma has shifted to the lower third of the esophagus. Unfortunately, esophageal carcinoma is often diagnosed late and, therefore, most therapeutic approaches are palliative. Advances have been made in staging procedures and therapeutic approaches. The guidelines emphasize that palpable advances have been made in the treatment of locoregional esophageal carcinoma. Similarly, endoscopic palliation of esophageal carcinoma has improved substantially because of improving technology. New chemotherapeutic agents are on the horizon, including antireceptor agents, vaccines, gene therapy, and anti-angiogenic agents. The panel expects numerous future advances in the treatment of esophageal carcinoma.

Original languageEnglish
Pages (from-to)328-347
Number of pages20
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume4
Issue number4
Publication statusPublished - Apr 2006
Externally publishedYes

Fingerprint

Esophageal Neoplasms
Practice Guidelines
Carcinoma
Active Immunotherapy
Hiatal Hernia
Barrett Esophagus
Therapeutics
Gastroesophageal Reflux
North America
Genetic Therapy
Esophagus
Adenocarcinoma
Obesity
Guidelines
Technology
Incidence
Health

Keywords

  • Chemoradiation
  • Chemotherapy
  • Combined modality therapy
  • Esophageal carcinoma
  • NCCN Clinical Practice Guidelines
  • Resection
  • Surgery

ASJC Scopus subject areas

  • Oncology

Cite this

Ajani, J., Bekaii-Saab, T., D'Amico, T. A., Fuchs, C., Gibson, M. K., Goldberg, M., ... Yen, Y. (2006). Esophageal cancer: Clinical Practice Guidelines in oncology™. JNCCN Journal of the National Comprehensive Cancer Network, 4(4), 328-347.

Esophageal cancer : Clinical Practice Guidelines in oncology™. / Ajani, Jaffer; Bekaii-Saab, Tanios; D'Amico, Thomas A.; Fuchs, Charles; Gibson, Michael K.; Goldberg, Melvyn; Hayman, James A.; Ilson, David H.; Javle, Milind; Kelley, Scott; Kurtz, Robert C.; Locker, Gershon Yehuda; Meropol, Neal J.; Minsky, Bruce D.; Orringer, Mark B.; Osarogiagbon, Raymond U.; Posey, James A.; Roth, Jack; Sasson, Aaron R.; Swisher, Stephen G.; Wood, Douglas E.; Yen, Yun.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 4, No. 4, 04.2006, p. 328-347.

Research output: Contribution to journalArticle

Ajani, J, Bekaii-Saab, T, D'Amico, TA, Fuchs, C, Gibson, MK, Goldberg, M, Hayman, JA, Ilson, DH, Javle, M, Kelley, S, Kurtz, RC, Locker, GY, Meropol, NJ, Minsky, BD, Orringer, MB, Osarogiagbon, RU, Posey, JA, Roth, J, Sasson, AR, Swisher, SG, Wood, DE & Yen, Y 2006, 'Esophageal cancer: Clinical Practice Guidelines in oncology™', JNCCN Journal of the National Comprehensive Cancer Network, vol. 4, no. 4, pp. 328-347.
Ajani J, Bekaii-Saab T, D'Amico TA, Fuchs C, Gibson MK, Goldberg M et al. Esophageal cancer: Clinical Practice Guidelines in oncology™. JNCCN Journal of the National Comprehensive Cancer Network. 2006 Apr;4(4):328-347.
Ajani, Jaffer ; Bekaii-Saab, Tanios ; D'Amico, Thomas A. ; Fuchs, Charles ; Gibson, Michael K. ; Goldberg, Melvyn ; Hayman, James A. ; Ilson, David H. ; Javle, Milind ; Kelley, Scott ; Kurtz, Robert C. ; Locker, Gershon Yehuda ; Meropol, Neal J. ; Minsky, Bruce D. ; Orringer, Mark B. ; Osarogiagbon, Raymond U. ; Posey, James A. ; Roth, Jack ; Sasson, Aaron R. ; Swisher, Stephen G. ; Wood, Douglas E. ; Yen, Yun. / Esophageal cancer : Clinical Practice Guidelines in oncology™. In: JNCCN Journal of the National Comprehensive Cancer Network. 2006 ; Vol. 4, No. 4. pp. 328-347.
@article{eaaa5aba9bb744b9b383d12c7c7fc035,
title = "Esophageal cancer: Clinical Practice Guidelines in oncology™",
abstract = "Esophageal cancer is a major health hazard in many parts of the world. The incidence of adenocarcinoma is increasing in white men, particularly in the nonendemic areas such as North America and many Western European countries. Barrett's metaplasia, gastroesophageal reflux, hiatal hernia, and obesity are believed to be contributing factors. In addition, the most common location of esophageal carcinoma has shifted to the lower third of the esophagus. Unfortunately, esophageal carcinoma is often diagnosed late and, therefore, most therapeutic approaches are palliative. Advances have been made in staging procedures and therapeutic approaches. The guidelines emphasize that palpable advances have been made in the treatment of locoregional esophageal carcinoma. Similarly, endoscopic palliation of esophageal carcinoma has improved substantially because of improving technology. New chemotherapeutic agents are on the horizon, including antireceptor agents, vaccines, gene therapy, and anti-angiogenic agents. The panel expects numerous future advances in the treatment of esophageal carcinoma.",
keywords = "Chemoradiation, Chemotherapy, Combined modality therapy, Esophageal carcinoma, NCCN Clinical Practice Guidelines, Resection, Surgery",
author = "Jaffer Ajani and Tanios Bekaii-Saab and D'Amico, {Thomas A.} and Charles Fuchs and Gibson, {Michael K.} and Melvyn Goldberg and Hayman, {James A.} and Ilson, {David H.} and Milind Javle and Scott Kelley and Kurtz, {Robert C.} and Locker, {Gershon Yehuda} and Meropol, {Neal J.} and Minsky, {Bruce D.} and Orringer, {Mark B.} and Osarogiagbon, {Raymond U.} and Posey, {James A.} and Jack Roth and Sasson, {Aaron R.} and Swisher, {Stephen G.} and Wood, {Douglas E.} and Yun Yen",
year = "2006",
month = "4",
language = "English",
volume = "4",
pages = "328--347",
journal = "Journal of the National Comprehensive Cancer Network : JNCCN",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "4",

}

TY - JOUR

T1 - Esophageal cancer

T2 - Clinical Practice Guidelines in oncology™

AU - Ajani, Jaffer

AU - Bekaii-Saab, Tanios

AU - D'Amico, Thomas A.

AU - Fuchs, Charles

AU - Gibson, Michael K.

AU - Goldberg, Melvyn

AU - Hayman, James A.

AU - Ilson, David H.

AU - Javle, Milind

AU - Kelley, Scott

AU - Kurtz, Robert C.

AU - Locker, Gershon Yehuda

AU - Meropol, Neal J.

AU - Minsky, Bruce D.

AU - Orringer, Mark B.

AU - Osarogiagbon, Raymond U.

AU - Posey, James A.

AU - Roth, Jack

AU - Sasson, Aaron R.

AU - Swisher, Stephen G.

AU - Wood, Douglas E.

AU - Yen, Yun

PY - 2006/4

Y1 - 2006/4

N2 - Esophageal cancer is a major health hazard in many parts of the world. The incidence of adenocarcinoma is increasing in white men, particularly in the nonendemic areas such as North America and many Western European countries. Barrett's metaplasia, gastroesophageal reflux, hiatal hernia, and obesity are believed to be contributing factors. In addition, the most common location of esophageal carcinoma has shifted to the lower third of the esophagus. Unfortunately, esophageal carcinoma is often diagnosed late and, therefore, most therapeutic approaches are palliative. Advances have been made in staging procedures and therapeutic approaches. The guidelines emphasize that palpable advances have been made in the treatment of locoregional esophageal carcinoma. Similarly, endoscopic palliation of esophageal carcinoma has improved substantially because of improving technology. New chemotherapeutic agents are on the horizon, including antireceptor agents, vaccines, gene therapy, and anti-angiogenic agents. The panel expects numerous future advances in the treatment of esophageal carcinoma.

AB - Esophageal cancer is a major health hazard in many parts of the world. The incidence of adenocarcinoma is increasing in white men, particularly in the nonendemic areas such as North America and many Western European countries. Barrett's metaplasia, gastroesophageal reflux, hiatal hernia, and obesity are believed to be contributing factors. In addition, the most common location of esophageal carcinoma has shifted to the lower third of the esophagus. Unfortunately, esophageal carcinoma is often diagnosed late and, therefore, most therapeutic approaches are palliative. Advances have been made in staging procedures and therapeutic approaches. The guidelines emphasize that palpable advances have been made in the treatment of locoregional esophageal carcinoma. Similarly, endoscopic palliation of esophageal carcinoma has improved substantially because of improving technology. New chemotherapeutic agents are on the horizon, including antireceptor agents, vaccines, gene therapy, and anti-angiogenic agents. The panel expects numerous future advances in the treatment of esophageal carcinoma.

KW - Chemoradiation

KW - Chemotherapy

KW - Combined modality therapy

KW - Esophageal carcinoma

KW - NCCN Clinical Practice Guidelines

KW - Resection

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=33747147863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747147863&partnerID=8YFLogxK

M3 - Article

C2 - 16569387

AN - SCOPUS:33747147863

VL - 4

SP - 328

EP - 347

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

SN - 1540-1405

IS - 4

ER -